TCTR20210525005尚未招募不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Patients with hepatocellular carcinoma
排除标准
- •1. Anaphylaxis to SARS-CoV-2 vaccine
- •2. Pregnancy or lactation
研究者
相似试验
已完成
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipientsImmunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipientsliver transplant, vaccine, COVID-19, SARS-CoV-2, safetyTCTR20210526004Faculty of medicine, Chulalongkorn university60
Unknown
3 期
Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older.COVID-19PACTR20201152310190334,520
进行中（未招募）
1 期
Study of Recombinant Protein Vaccines with Adjuvant as a Primary Series and as a Booster Dose against COVID-19 in Adults 18 Years of Age and OlderCOVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-003370-41-ESSanofi Pasteur Inc.5,412
招募中
2 期
Immunogenicity and the safety of the COVID-19 vaccines available in Thailand.The immune response after COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, Sputnik V, ChAdOx1, coronavac, Sinovac.TCTR20210517006Chulabhorn Royal Academy3,000
招募中
1 期
Phase I clinical trial of Osvid-19 inactivated vaccine for Covid-19 (Osve Pharmaceutical Company)COVID-19 disease.COVID-19, virus identifiedU07.1IRCT20210622051670N1Osve pharmaceutical company40